Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus first-line DOX chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2000030877Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Huashan Hospital. Primary endpoints: Objective response rate and Safety. Started Nov 2019; status: recruiting.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000030877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030877.